| CAS NO: | 2305052-86-0 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| Cas No. | 2305052-86-0 |
| 分子式 | C21H17ClN4O2 |
| 分子量 | 392.84 |
| 溶解度 | DMSO : 150 mg/mL (381.83 mM; Need ultrasonic) |
| 储存条件 | 4°C, stored under nitrogen |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | BPK-25, an active acrylamide, promotes degradation of nucleosome remodeling and deacetylation (NuRD) complex proteins by a post-translational mechanism involving covalent protein engagement. BPK-25 inhibits TMEM173 activation by the cyclic dinucleotide ligand cGAMP[1]. BPK-25 (10 μM; 5 hours) inhibits TMEM173 activation by the cyclic dinucleotide ligand cGAMP[1]. BPK-25 (10 μM; 24 hours) suppresses NF-κB activation blocks nuclear factor of activated T-cells (NFAT) activation, as measured by >50% reductions in IκBα phosphorylation[1]. BPK-25 (10 μM; 4 hours) also reduces NFATc2 expression in T cells[1]. BPK-25 (0.1, 1, 5, 10, 20 μM; 24 hours) promotes the striking and selective reduction of several proteins in the nucleosome remodeling and deacetylation (NuRD) complex in a concentration- and time-dependent manner. BPK-25 does not have corresponding changes in mRNA expression[1]. A non-electrophilic propanamide analog of BPK-25 (BPK-25-ctrl) does not suppress T cell activation or affect NuRD complex proteins in T cells[1]. [1]. Ekaterina V Vinogradova, et al. An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells. Cell. 2020 Aug 20;182(4):1009-1026.e29. |
m.cnreagent.com